Jerini AG

Drug discovery and drug development

Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialise the SPOT™ technology. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company and venture capital was applied for. Currently, Jerini has 108 Employees and has raised €71 mio. in total venture capital.

Jens Schneider-Mergener, Prof., CEO
Jochen Knolle, Dr., CSO
Adi Hoess, Dr., CCO
Berndt Modig, CFO

Karl-Gerhard Seifert, Dr., Chairman
Günter Stock, Prof. Dr., Dr. h.c.
Hubert Birner, Dr.
Stephan Goetz, Dr.
Zsolt Lavotha
Björn Odlander, Dr.

Ronald Frank, Dr.
Carl D. Johnson, Dr.
Tom Gadek, Dr.
Horst Kessler, Prof. Dr.
Simon Campbell, Dr.

Invalidenstr. 130
10115 Berlin
Germany
Phone: +49-30-978-930
Fax: +49-30-9789-3105

Jerini AG has built a pipeline of several preclinical and two clinical projects (phase II) with its proprietary Peptides-to-Drugs (P2D) discovery platform. P2D addresses extra- and intra-cellular targets and was developed to overcome the limitations of conventional HTS or protein-based discovery approaches. P2D includes massive parallel syntheses and screening of peptide leads, pharmacophore identification and tansformation into peptidomimetic and/or small molecule drugs. The peptide lead to a small molecule conversion step is a direct process that does not include any intermediate modifications of the peptide lead. It is supported by medicinal chemistry and cheminformatics and guided by matching the pharmacophore derived from massive peptide SAR data information against a virtual small molecule library. Jerini’s platform allows the rapid identification and/or optimisation of agonists and antagonists for target proteins.

The company’s lead product is Icatibant, a highly potent and selective peptidomimetic Bradykinin BK 2 receptor antagonist.

Icatibant is currently in Phase III clinical trials for the subcutaneous treatment of hereditary angioedema.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.